These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37071590)

  • 1. Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey.
    Elwitigala J; Rajapaksa L; Inzaule SC; Ariyaratne KAM; Jayasena S; Kurle S; Patil A; Kale D; Siriwardna L; Samaraweera G; Perera H; Jayakody C
    J Antimicrob Chemother; 2023 Jun; 78(6):1476-1479. PubMed ID: 37071590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.
    Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G
    J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?
    Kouamou V; Mavetera J; Manasa J; Ndhlovu CE; Katzenstein D; McGregor AM
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):776-783. PubMed ID: 33430681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Pretreatment HIV-1 Drug Resistance in Armenia in 2017-2018 and 2020-2021 following a WHO Survey.
    Kirichenko A; Kireev D; Lapovok I; Shlykova A; Lopatukhin A; Pokrovskaya A; Ladnaya N; Grigoryan T; Petrosyan A; Sarhatyan T; Sargsyants N; Hovsepyan T; Ghazaryan H; Hovakimyan H; Martoyan S; Pokrovsky V
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.
    Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS
    PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China.
    Lan Y; Xin R; Cai W; Deng X; Li L; Li F; Cai X; Tang X; Fan Q; Hu F
    J Antimicrob Chemother; 2020 Jul; 75(7):1925-1931. PubMed ID: 32300784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.
    McCluskey SM; Lee GQ; Kamelian K; Kembabazi A; Musinguzi N; Bwana MB; Muzoora C; Haberer JE; Hunt PW; Martin JN; Boum Y; Bangsberg DR; Harrigan PR; Siedner MJ
    AIDS Patient Care STDS; 2018 Jul; 32(7):257-264. PubMed ID: 29985647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Investigation of HIV-1 Primary Drug Resistance Among Newly Diagnosed Treatment-Naïve HIV-1 Individuals in Hebei, China.
    Lu X; Chen S; Zhao H; Li Y; Wang Y; Zhang Y; Lian K; Zhao C; Cui Z
    AIDS Res Hum Retroviruses; 2018 Dec; 34(12):1083-1089. PubMed ID: 29999406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru.
    Trebelcock WL; Lama JR; Duerr A; Sanchez H; Cabello R; Gilada T; Segura P; Reisner SL; Mayer KH; Mullins J; Bender Ignacio RA
    J Int AIDS Soc; 2019 Nov; 22(11):e25411. PubMed ID: 31773888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
    Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF;
    Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 pretreatment drug resistance and genetic transmission network in the southwest border region of China.
    Li D; Chen H; Li H; Ma Y; Dong L; Dai J; Jin X; Yang M; Zeng Z; Sun P; Song Z; Chen M
    BMC Infect Dis; 2022 Sep; 22(1):741. PubMed ID: 36117159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
    Weng YW; Chen IT; Tsai HC; Wu KS; Tseng YT; Sy CL; Chen JK; Lee SS; Chen YS
    BMC Infect Dis; 2019 Aug; 19(1):741. PubMed ID: 31443633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C
    Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV drug resistance in persons initiating or reinitiating first-line antiretroviral therapy in Paraguay: Results of a National Patient Survey.
    Aguilar G; Truong HM; Ovelar P; Samudio T; Lopez G; García-Morales C; Tapia-Trejo D; López-Sánchez DM; Ávila-Ríos S; Giron A; De Arias AR; Rios-Gonzalez C; McFarland W
    J Med Virol; 2022 Oct; 94(10):5061-5065. PubMed ID: 35701340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-naïve subjects.
    Gupta S; Lataillade M; Kyriakides TC; Chiarella J; St John EP; Webb S; Moreno EA; Simen BB; Kozal MJ
    Viruses; 2014 Sep; 6(9):3428-37. PubMed ID: 25256391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay-Results of a Nationally Representative Survey, 2018-2019.
    Flieller R; Cabrera S; Ruchansky D; Girón-Callejas A; Brasesco M; Pérez D; Chiparelli H; García-Morales C; Tapia-Trejo D; Monreal-Flores J; Ravasi G; Jordan MR; Ávila-Ríos S
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.